Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Marinus (MRNS)
NASDAQ:MRNS
Holding MRNS?
Track your performance easily
MRNS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.22 - $10.50
Previous CloseN/A
Volume358.63K
Average Volume (3M)2.75M
Market Cap
$29.93M
Enterprise Value$153.73M
Total Cash (Recent Filing)$30.10M
Total Debt (Recent Filing)$1.74M
Price to Earnings (P/E)―
Beta2.20
Next Earnings
Mar 11, 2025EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.47
Shares Outstanding55,218,487
10 Day Avg. Volume2,152,448
30 Day Avg. Volume2,746,467
Standard Deviation0.28
R-Squared0.04
Alpha-0.00194
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.95
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market Cap5.14
Enterprise Value/Revenue4.89
Enterprise Value/Gross Profit5.29
Enterprise Value/Ebitda-1.19
Forecast
1Y Price Target
$1.57Price Target Upside190.74% Upside
Rating ConsensusHold
Number of Analyst Covering7
Marinus News
PremiumCompany Announcements
Marinus Ends Agreements Amid Strategic Review
PremiumCompany Announcements
Marinus Pharmaceuticals Merges with Immedica Pharma AB
PremiumCompany Announcements
Marinus Unveils Management Retention and Severance PlansPremiumCompany Announcements
Marinus Pharmaceuticals Faces Financial Turmoil Amidst Class Action Lawsuit
PremiumCompany Announcements
Marinus Pharmaceuticals Reports Q3 Growth in ZTALMY RevenueBulls Say, Bears Say
Bulls Say
Financial PerformanceZtalmy performance as solid with Q3 2024 net product revenue of $8.5 million, up 56% Y/Y.
Partnership PotentialThere is potential for a partner or acquirer for ZTALMY given its established launch success in patients with CDKL5-deficiency disorder.
Product ApprovalZtalmy (oral ganaxolone) is approved in several countries as the only treatment for CDKL5 deficiency disorder.
Bears Say
Clinical TrialsThe Phase III trial of ganaxolone in TSC failed to meet the primary endpoint, raising concerns about the drug's efficacy.
Financial PerformanceMarinus reported a Q3 net loss of $24.2MM or $0.42/share, highlighting financial challenges.
Strategic DirectionThe company has begun to explore strategic alternatives after discontinuing further clinical development of ganaxolone, indicating uncertainty in future plans.
---
Ownership Overview
1.34% Insiders
7.29% Mutual Funds
0.11% Other Institutional Investors
86.28% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRNS FAQ
What was Marinus’s price range in the past 12 months?
Marinus lowest stock price was $0.22 and its highest was $10.50 in the past 12 months.
What is Marinus’s market cap?
Marinus’s market cap is $29.93M.
When is Marinus’s upcoming earnings report date?
Marinus’s upcoming earnings report date is Mar 11, 2025 which is in 40 days.
How were Marinus’s earnings last quarter?
Marinus released its earnings results on Nov 12, 2024. The company reported -$0.42 earnings per share for the quarter, missing the consensus estimate of -$0.409 by -$0.011.
Is Marinus overvalued?
According to Wall Street analysts Marinus’s price is currently Undervalued.
Does Marinus pay dividends?
Marinus does not currently pay dividends.
What is Marinus’s EPS estimate?
Marinus’s EPS estimate is -0.33.
How many shares outstanding does Marinus have?
Marinus has 55,218,487 shares outstanding.
What happened to Marinus’s price movement after its last earnings report?
Marinus reported an EPS of -$0.42 in its last earnings report, missing expectations of -$0.409. Following the earnings report the stock price went down -11.765%.
Which hedge fund is a major shareholder of Marinus?
Among the largest hedge funds holding Marinus’s share is Woodline Partners LP. It holds Marinus’s shares valued at 2M.
---
Marinus Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.57 (190.74% Upside)
$1.57 (190.74% Upside)
Blogger Sentiment
Neutral
MRNS Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 11.8%
Last 30 Days ▼ 11.8%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-94.50%
12-Months-Change
Fundamentals
Return on Equity
210.50%
Trailing 12-Months
Asset Growth
-68.32%
Trailing 12-Months
Company Description
Marinus
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.
---
MRNS Stock 12 Month Forecast
Average Price Target
$1.57
▲(190.74% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Catalyst Pharma
―
Sarepta Therapeutics
―
PTC Therapeutics
―
SAGE Therapeutics
―
Best Analysts Covering MRNS
1 Year
1 Year Success Rate
5/12 ratings generated profit
1 Year Average Return
+5.22%
reiterated a buy rating 3 months ago
Copying Jay Olson's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of +5.22% per trade.
---